Literature DB >> 210882

Effects of 4-aminopyridine on neuromuscular transmission.

H Lundh.   

Abstract

4-Aminopyridine (4-AP) powerfully increases transmitter release from motor nerve terminals of rat and frog skeletal muscle in response to single nerve impulses. The drug also enhances transmitter release during repetitive nerve activity but, at D-tubocurarine-blocked endplates, only the first impulses cause increased transmitter release at stimulation frequencies at or above 50 Hz. At magnesium- and botulinum-poisoned endplates, 4-AP potentiates transmitter release at every stimulus during tetanic nerve stimulation and restores neuromuscular transmission. Spontaneous transmitter release in the rat is not affected by the drug, but at some frog endplates miniature endplate potential (mepp) frequency increases. The drug has no post-synaptic action, as evidenced by its lack of effect on amplitude or time course of mepps. Decreasing the temperature from 37 to 15 degrees C does not abolish the effect of 4-AP on neuromuscular transmission. In the presence of 4-AP, single nerve impulses produce repetitive spontaneous activity in the nerve terminal of the frog nerve-muscle preparation. Experiments on the mode of action of 4-AP suggest that the drug increases transmitter release by enhancing the influx of calcium ions during depolarization of the nerve terminal.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 210882     DOI: 10.1016/0006-8993(78)90409-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  34 in total

1.  Multiple potassium conductances at the mammalian motor nerve terminal.

Authors:  D A Saint; D M Quastel; Y Y Guan
Journal:  Pflugers Arch       Date:  1987-11       Impact factor: 3.657

2.  Clinically Relevant Levels of 4-Aminopyridine Strengthen Physiological Responses in Intact Motor Circuits in Rats, Especially After Pyramidal Tract Injury.

Authors:  Anil Sindhurakar; Asht M Mishra; Disha Gupta; Jennifer F Iaci; Tom J Parry; Jason B Carmel
Journal:  Neurorehabil Neural Repair       Date:  2017-01-20       Impact factor: 3.919

3.  Effect of 4-aminopyridine on muscle contractility in the cat [proceedings].

Authors:  W C Bowman; I W Rodger; A O Savage
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

4.  A further study of the neuromuscular effects of vesamicol (AH5183) and of its enantiomer specificity.

Authors:  D Estrella; K L Green; C Prior; J Dempster; R F Halliwell; R S Jacobs; S M Parsons; R L Parsons; I G Marshall
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

5.  Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions.

Authors:  F Giovannini; E Sher; R Webster; J Boot; B Lang
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

6.  Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction.

Authors:  S D Provan; M D Miyamoto
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

7.  Stimulation of phrenic nerve activity by an acetylcholine releasing drug: 4-aminopyridine.

Authors:  H Folgering; J Rutten; S Agoston
Journal:  Pflugers Arch       Date:  1979-03-16       Impact factor: 3.657

8.  Effect of 4-Aminopyridine on Action Potential Parameters in Isolated Dog Purkinje Fibers.

Authors:  George Thomas; Brian Klatt; Andrew Blight
Journal:  Arch Drug Inf       Date:  2010-03

9.  Presynaptic actions of 4-aminopyridine and gamma-aminobutyric acid on rat sympathetic ganglia in vitro.

Authors:  M Galvan; P Grafe; G ten Bruggencate
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-11       Impact factor: 3.000

10.  Neuromuscular transmission without sodium activation of the presynaptic nerve terminal in the lobster.

Authors:  N Kawai; A Niwa
Journal:  J Physiol       Date:  1980-08       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.